Appili net loss widens 100% to CAD 1 million in Q3 FY26

• Appili posted an IFRS net loss of CAD 1 million, widening from CAD 0.5 million a year earlier.
• Loss per share rose to CAD 0.01.
• Results reflected CAD 2.6 million less government assistance, partly offset by CAD 1.2 million lower R&D expense.
• Cash fell to CAD 200,000 as of Dec. 31, 2025, from CAD 1.2 million as of March 31, 2025.
• Strategy shifts toward biodefence; ATI-1801 remains key near-term regulatory opportunity, with FDA approval targeted as early as Q4 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Appili Therapeutics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608141700NEWSFILECNPR____20260814_309716_1) on August 14, 2026, and is solely responsible for the information contained therein.